T 1592/11 du 11.05.2015
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2015:T159211.20150511
- Date de la décision
- 11 mai 2015
- Numéro de l'affaire
- T 1592/11
- Requête en révision de
- -
- Numéro de la demande
- 01272094.2
- Classe de la CIB
- A61M 5/315A61M 5/145A61M 5/172A61M 5/142A61M 5/24
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- PEN-TYPE INJECTOR HAVING AN ELECTRONIC CONTROL UNIT
- Nom du demandeur
- DCA Design International Limited
- Nom de l'opposant
- Novo Nordisk A/S
- Chambre
- 3.2.02
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)European Patent Convention Art 53(c)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 84European Patent Convention R 115(2)European Patent Convention R 99(2)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 15(3)
- Mots-clés
- Admissibility of appeal - (yes)
Admissibility of late-filed documents (yes); remittal (no)
Method of treatment by therapy (yes)
Support and clarity of disclaimer (no)
Added subject-matter (no) - auxiliary request XIIIii
Novelty (yes)
Novelty - auxiliary request XIIIii - Exergue
- -
- Affaires citantes
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of:
- claims 1 and 2 of auxiliary request XIIIii filed during oral proceedings;
- pages 2, 2a and 3 to 5 of the adapted description filed during oral proceedings; and
- figures 1 to 3 and 3A of the patent as granted.